Emergent BioSolutions Appoints New Directors, Adjusts CFO Compensation
Ticker: EBS · Form: 8-K · Filed: Jul 30, 2024 · CIK: 1367644
| Field | Detail |
|---|---|
| Company | Emergent Biosolutions Inc. (EBS) |
| Form Type | 8-K |
| Filed Date | Jul 30, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, executive-compensation, board-of-directors
TL;DR
Emergent BioSolutions adds two directors and updates CFO pay package.
AI Summary
Emergent BioSolutions Inc. announced on July 30, 2024, changes in its board of directors and executive compensation. The company elected two new directors, Robert L. Johnson and Dr. David M. Glick, to its Board, effective immediately. Additionally, the company entered into a new employment agreement with its Chief Financial Officer, Richard S. Lindahl, which includes a base salary of $475,000 and potential performance-based bonuses.
Why It Matters
The appointment of new directors and changes to executive compensation can signal shifts in company strategy and governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Changes in board composition and executive compensation can indicate internal shifts or strategic realignments that may carry inherent risks.
Key Numbers
- $475,000 — CFO Base Salary (New annual base salary for Richard S. Lindahl)
Key Players & Entities
- Emergent BioSolutions Inc. (company) — Registrant
- Robert L. Johnson (person) — Newly Elected Director
- Dr. David M. Glick (person) — Newly Elected Director
- Richard S. Lindahl (person) — Chief Financial Officer
- $475,000 (dollar_amount) — CFO's new base salary
FAQ
Who were the new directors elected to Emergent BioSolutions' Board?
Robert L. Johnson and Dr. David M. Glick were elected as new directors.
When were the new directors' appointments effective?
The appointments of Robert L. Johnson and Dr. David M. Glick were effective immediately as of July 30, 2024.
What is the new base salary for the Chief Financial Officer?
The new base salary for Richard S. Lindahl, the Chief Financial Officer, is $475,000 per year.
What other compensation components are included in the CFO's new agreement?
The new employment agreement for Richard S. Lindahl includes potential performance-based bonuses.
What is the filing date of this 8-K report?
This 8-K report was filed on July 30, 2024.
Filing Stats: 426 words · 2 min read · ~1 pages · Grade level 12.4 · Accepted 2024-07-30 16:30:51
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value per share EBS New York Stock
Filing Documents
- ebs-20240730.htm (8-K) — 24KB
- 0001367644-24-000130.txt ( ) — 147KB
- ebs-20240730.xsd (EX-101.SCH) — 2KB
- ebs-20240730_lab.xml (EX-101.LAB) — 22KB
- ebs-20240730_pre.xml (EX-101.PRE) — 13KB
- ebs-20240730_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. EMERGENT BIOSOLUTIONS INC. Dated: July 30, 2024 By: /s/ RICHARD S. LINDAHL Name: Richard S. Lindahl Title: Executive Vice President, Chief Financial Officer and Treasurer